Anonymous ID: ea4e6e July 18, 2023, 1:48 p.m. No.19202479   🗄️.is 🔗kun

Repost frm (lb), anon finds this prescient.

 

Prep advice received in an email

YMMV

 

"Any household with less than a year+ of food, meds, water capability will be the most dangerous people around in a war/ collapse/grid down environment, and that will be about 90% of the population. Even if a lot die off in the first phase, their homes will be high risk, yet useless, scavenging opportunities as they are not prepped.

This is what I have been teaching for a long time:

"Buy food! Grow food! Raise food! Store food!

Store water, have triple redundancy to procure, treat, and purify water. (distill, filter, iodine tabs, chlorine, etc)

Have the knowledge and ability to manage human waste.

Have antibiotics, trauma first aid skills and resources, and the means to manage wounds long term without escalation to higher care (learn and practice basic first aid and above- TCCC Tactical Combat Casualty Care w/ MARCH-E algorithm).

Have hand tools and skills and reps for defense, repair, food, etc

Have physical fitness and endurance as a priority.

Experience fasting.

Have situational awareness skills trained and drilled. Hand to hand self defense (especially from abduction, mandatory skills for kids and ladies)

Evacs and rally points known, trained, and drilled.

Sound, light, and movement discipline understanding and practice

Agreed upon rules of engagement with tribe/mag, including lines of fire, and "friendly" ID and approach

Agreed upon rationing plan with family, with group.

Delegation of labor and tasks plan.

Comms plans.

Have bug out plans known and drilled.

Drill at night, in bad weather, with simulated injuries, broken/lost gear.

Have known triggers- if A happens we do X. Consider - bad guys, fire, tornado, long term power outage, and rate and direction of approach.

Have separated party plans (if comms and power are offline while group is separated or away from primary location).

Have supply caches on bug out routes or rally locations, etc

Have paper maps of AO and routes. Know local topography and that on bug out routes.

Have working knowledge of walking distance water sources, caves, mines.

Have the ability to downsize from primary location to vehicle to foot, without need to repack or commit time.

Decide what is worth defending with your life and find consensus with team- food? location? people? etc

Share afterlife requests, and terminal injury/illness preferences.

Pray.

Endure.

 

there is probably more, but my notebook is away from me ATM. :)

 

All plans should be PACE fortified -

Primary

Alternate

Contingency

Emergency"

Anonymous ID: ea4e6e July 18, 2023, 1:55 p.m. No.19202528   🗄️.is 🔗kun   >>3097

>>19202492

as a supplier delivering on a US govt contract for DARPA, how can they be sued? They built an order to spec and were never charged with breach of contract, so in business terms/law, they fulfilled their end of the agreement.

 

Pfizer AND Moderna were contracted assets for the US MILITARY via darpa, aka the DOD and US gov't. In 2013. For mrna bio-nano technology

 

darpa Awards Moderna therapeutics A Grant For Up to $25 Million to Develop Messenger RNA therapeutics™ (2013)

https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html

 

CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ – Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (darpa) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.

 

Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.

 

"We are honored to be chosen by darpa for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of Moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."

 

This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from darpa in March to begin work on the project.

 

This grant is part of a darpa program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.

 

Pfizer Awarded darpa Biodefense Contract - DoD Daily Contracts 2013

https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/

 

Pfizer, Inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).

 

"warp speed". uh huh…